RT Journal Article
T1 Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
A1 Voorham, Jaco
A1 Baldi, Simonetta
A1 Santoro, Luigi
A1 Kerkhof, Marjan
A1 Contoli, Marco
A1 Fabbri, Leonardo M
A1 Kerstjens, Huib A M
A1 Luis López-Campos, Jose
A1 Roche, Nicolas
A1 Singh, Dave
A1 Vogelmeier, Claus F
A1 Price, David B
K1 chronic obstructive pulmonary disease
K1 comparative effectiveness
K1 electronic health records
K1 heterogeneity
K1 observational
K1 real-world
AB This study aimed to evaluate the non-inferiority of initiating extrafine beclometasone dipropionate/formoterol fumarate (BDP/FF) versus double bronchodilation (long-acting beta-agonists [LABA]/long-acting muscarinic antagonists [LAMA]) among patients with a history of chronic obstructive pulmonary disease (COPD) exacerbations. A historical cohort study was conducted using data from the UK's Optimum Patient Care Research Database. Patients with COPD ≥40 years at diagnosis were included if they initiated extrafine BDP/FF or any LABA/LAMA double therapy as a step-up from no maintenance therapy or monotherapy with inhaled corticosteroids (ICS), LAMA, or LABA and a history of ≥2 moderate/severe exacerbations in the previous two years. The primary outcome was exacerbation rate from therapy initiation until a relevant therapy change or end of follow-up. Secondary outcomes included rate of acute respiratory events, acute oral corticosteroids (OCS) courses, and antibiotic prescriptions with lower respiratory indication, modified Medical Research Council score (mMRC) ≥2, and time to first pneumonia diagnosis. The non-inferiority boundary was set at a relative difference of 15% on the ratio scale. Five potential treatment effect modifiers were investigated. A total of 1735 patients initiated extrafine BDP/FF and 2450 patients initiated LABA/LAMA. The mean age was 70 years, 51% were male, 41% current smokers, and 85% had FEV1  This study found that stepping up to extrafine BDP/FF from no maintenance or monotherapy was not inferior to stepping up to double bronchodilation therapy in patients with a history of exacerbations.
YR 2020
FD 2020-10-29
LK http://hdl.handle.net/10668/16549
UL http://hdl.handle.net/10668/16549
LA en
DS RISalud
RD Apr 10, 2025